BRIEF—Bioxodes appoints new chief executive

2013-founded Belgian biotech Bioxodes has appointed Marc Dechamps as chief executive, replacing the company’s founder, Edmond Godfroid, who will become chief operating officer (COO) as well as chief scientific officer (CSO).

Bioxodes specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases.

The company is gearing up for a Phase IIa trial for its lead candidate, Ir-CPI, in people with intracerebral hemorrhage (ICH).

Ir-CPI, a recombinant protein derived from a certain tick, is thought to block thrombus formation without impairing hemostasis.

There is currently no treatment option for people with ICH which is able to stop acute secondary damage within three days.

Mr Godfroid has several decades of experience in the pharma industry, particularly in the areas of strategic development and marketing, including at GSK and ViiV Healthcare.